|
全民健康保險藥品給付規定 |
|
See related Dysport inj[儷緻 注射劑] information |
|
|
|
製造商 |
IPSEN |
|
代理/經銷商 |
Centapharm |
|
成份 |
Clostridium botulinum type A toxin-haemagglutinin complex |
|
適應症 |
Spasticity of the arm in adult patients following a stroke; dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients ≥2 years; spasmodic torticollis in adults; blepharospasm in adults; hemifacial spasm in adults; treatment of moderate to severe glabellar lines. |
|
用量 |
Pediatric cerebral palsy spasticity Children ≥ 2 years 30 u/kg body weight as a divided dose between both calf muscles. Max: 1000 u/patient. Spasmodic torticollis Initially 500 u given in a divided dose & administered to the 2-3 most active neck muscles. Bilateral blepharospasm Initially 120 u/eye repeated every 8 weeks or as required. Hemifacial spasm Treat as for unilateral blepharospasm, with other affected facial muscles each being injected as needed. Post stroke: Arm spasticity: Recommended dose is 1000 u in total distributed amongst five muscles: BB (300-400 u); FDP (150 u); FDS (150-250 u); FCU (150 u); PCR (150 u). Glabellar lines 10 u (0.05 mL) IM into each of these 5 sites: 2 in each corrugator muscle & 1 into the procerus muscle for a total dose of 50 u. |
|
過量 |
View Dysport[儷緻] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Pregnancy. |
|
注意事項 |
Subclinical or clinical evidence of marked defective neuromuscular transmission. |
|
不良反應 |
Local weakness of skeletal muscles, urinary incontinence, inj site pain, dysphagia, dry mouth, voice changes, generalised weakness & visual disturbances (including diplopia & blurred vision), skin rash, flu-like symptoms, ptosis, keratitis, dry eyes, minor bruising & lid swelling.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
副作用 |
View Dysport[儷緻] side effects |
|
交互作用 |
[Click for Dysport[儷緻] detailed prescribing infomation]
View more drug interactions with Dysport[儷緻] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Dysport[儷緻] detailed prescribing infomation |
|
儲存 |
View Dysport[儷緻] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Dysport[儷緻] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Dysport[儷緻] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
|
|
Manufacturer: |
IPSEN |
|
Distributor: |
Centapharm
|
|
|
|
